Skip to main content

Table 3 Tumour size and the impact on endocrine function in the study population (n = 101) at baseline and after TSS

From: Post-operative volumes following endoscopic surgery for non-functioning pituitary macroadenomas are predictive of further intervention, but not endocrine outcomes

Preoperative tumour volume

Males (n = 62)

Females (n = 39)

p-value

 Mean tumour size (cm3) ± SD

8.88 ± 8.56

6.46 ± 5.05

0.12

 Age at surgery (years)

59.3 ± 13.3

0.35

 Individual hormone axis

Mean tumour size (cm3)

p-value

  • GH deficiency

8.45 ± 6.10

0.44

  • LH/FSH deficiency

8.81 ± 8.92

0.22

  • ACTH deficiency

7.17 ± 5.34

0.45

  • TSH deficiency

7.88 ± 6.41

0.93

Number of pituitary hormone deficiencies

 • 0

6.28 ± 4.18

0.69

 • 1–2

9.00 ± 9.88

 • ≥3

7.92 ± 5.91

Postoperative Tumour Residuum

 Mean tumour residuum size (cm3) ± SD

1.96 ± 4.46

 Number of pituitary hormone deficiencies

Mean tumour size (cm3)

p-value

  • 0

1.68 ± 2.29

0.44

  • 1–2

2.34 ± 6.39

  • ≥ 3

1.24 ± 2.07

 Extent of Resection (EOR)

  Mean EOR (%) ± SD

75.9 ± 21.8; Range: 3.4–100%

  Gross total resection (GTR)

7 (6.9%)

  Near total resection (≥90 % )

28 (27.7%), including 7 GTR

  Subtotal resection (75–89.9%)

39 (38.6%)

  Partial resection (< 75%)

30 (29.7%)

 Endocrine outcomes

Mean EOR (%) ± SD

p-value

  • New axis deficit (n = 25)

78.6 ± 23.5

0.48

  • Axis recovery (n = 16)

79.9 ± 16.9

0.45

  • Pituitary function preserved (n = 60)

73.8 ± 22.1

0.38

  1. The effects of the extent of tumour resection are studied on the appearance of new hormone deficits and on axis recovery. A p-value of < 0.05 is considered statistically significant